YiChang HEC ChangJiang Pharmaceutical Co. Ltd. Class H (HK:1558) has released an update.
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. has entered a significant licensing agreement with Apollo Therapeutics Group Limited, granting Apollo exclusive rights to develop and commercialize APL-18881 globally, except in China. Under this agreement, the company stands to receive up to $938 million in various payments, including milestone payments and royalties based on sales outside China. This collaboration represents a strategic move for YiChang HEC to expand its market reach and capitalize on its pharmaceutical innovations.
For further insights into HK:1558 stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Shareholder Alert for Flux Power Holdings, Inc. (NASDAQ:FLUX)
- ValueAct’s $1B Stake in Meta Platforms is a Constructive Not Activist Bet
- Spirit Airlines Plunges 63% on Possibility of Bankruptcy Deal Wiping Out Shareholders’ Wealth
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
